<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-02-01T07:27:59.335Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786053</article-id><article-id pub-id-type="doi">10.1093/ofid/ofaf012</article-id><article-id pub-id-type="publisher-id">ofaf012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials and Therapeutics</subject><subj-group subj-group-type="category-toc-heading"><subject>Brief Report</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive <italic toggle="yes">Staphylococcus aureus</italic> Bloodstream Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-0378-9753</contrib-id><name><surname>Kener</surname><given-names>Daisy</given-names></name><aff>
<institution>Department of Pharmacy, Intermountain Health Utah&#x02013;St George Regional Hospital</institution>, <addr-line>St George, Utah</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8301-4023</contrib-id><name><surname>Childress</surname><given-names>Darrell</given-names></name><aff>
<institution>Department of Pharmacy, Intermountain Health Utah&#x02013;St George Regional Hospital</institution>, <addr-line>St George, Utah</addr-line>, <country country="US">USA</country></aff><xref rid="ofaf012-cor1" ref-type="corresp"/><!--Darrell.Childress@imail.org--></contrib><contrib contrib-type="author"><name><surname>Andrus</surname><given-names>Ian</given-names></name><aff>
<institution>Department of Pharmacy, Intermountain Health Utah&#x02013;St George Regional Hospital</institution>, <addr-line>St George, Utah</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Olson</surname><given-names>Jared</given-names></name><aff>
<institution>Department of Pharmacy, Intermountain Health Utah&#x02013;Primary Children's Hospital</institution>, <addr-line>Salt Lake City, Utah</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Division of Pediatric Infectious Diseases, University of Utah</institution>, <addr-line>Salt Lake City, Utah</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1799-3315</contrib-id><name><surname>Webb</surname><given-names>Brandon</given-names></name><aff>
<institution>Division of Infectious Diseases, Intermountain Medical Center</institution>, <addr-line>Salt Lake City, Utah</addr-line>, <country country="US">USA</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="ofaf012-cor1">Correspondence: Darrell Childress, PharmD, BCPS, BCIDP, Department of Pharmacy 3, Intermountain Health Utah&#x02013;St George Regional Hospital, 1380 E Medical Center Dr, St George, UT 84790 (<email>Darrell.Childress@imail.org</email>).</corresp><fn id="FM1" fn-type="COI-statement"><p>
<bold>
<italic toggle="yes">Potential conflicts of interest.</italic>
</bold> All authors: No reported conflicts.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-01-17"><day>17</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>1</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>ofaf012</elocation-id><history><date date-type="received"><day>01</day><month>10</month><year>2024</year></date><date date-type="editorial-decision"><day>07</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2025</year></date><date date-type="corrected-typeset"><day>01</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="ofaf012.pdf"/><abstract><title>Abstract</title><p>Multiple observational studies in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> and enterococcal infections have suggested that higher doses of daptomycin may be associated with better clinical outcomes. However, optimal daptomycin dosing in methicillin-sensitive <italic toggle="yes">S aureus</italic> bloodstream infections remains unclear. In this multicentered, retrospective, observational cohort study, we compared standard dose daptomycin (&#x0003c;8&#x02005;mg/kg) vs high dose (&#x02265;8&#x02005;mg/kg) for methicillin-sensitive <italic toggle="yes">S aureus</italic> bloodstream infections. In a propensity-weighted model, the composite outcome of treatment failure within 90 days was lower in the high-dose group relative to the standard dose group (odds ratio, 0.496; 95% CI, .306&#x02013;.804). We did not detect any significant difference in safety outcomes.</p></abstract><kwd-group><kwd>bacteremia</kwd><kwd>blood stream infection</kwd><kwd>BSI</kwd><kwd>daptomycin</kwd><kwd>methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic></kwd><kwd>MSSA</kwd></kwd-group><counts><page-count count="5"/></counts></article-meta></front><body><p>
<italic toggle="yes">Staphylococcus aureus</italic> is the leading cause of bacteremia and is associated with higher rates of morbidity, mortality, and complicated infections [<xref rid="ofaf012-B1" ref-type="bibr">1&#x02013;3</xref>]. Antistaphylococcal &#x003b2;-lactams (ASBLs) such as nafcillin, oxacillin, and cefazolin (first-generation cephalosporin) are the preferred treatment for methicillin-sensitive <italic toggle="yes">S aureus</italic> (MSSA) bacteremia. However, these agents require multiple administrations per day and are not a viable option in some outpatient parenteral antibiotic therapy (OPAT) settings. Daptomycin is a cyclic lipopeptide antibiotic that is bactericidal in a concentration-dependent manner [<xref rid="ofaf012-B4" ref-type="bibr">4</xref>]. Daptomycin has several advantages, including once-daily administration and a similarly favorable safety profile as ASBLs, and unlike cefazolin, it may not be prone to in vitro inoculum effect against some MSSA strains [<xref rid="ofaf012-B5" ref-type="bibr">5</xref>, <xref rid="ofaf012-B6" ref-type="bibr">6</xref>]. Daptomycin is Food and Drug Administration approved for the treatment of <italic toggle="yes">S aureus</italic> bloodstream infections (BSIs) at a dose of 6-mg/kg intravenous infusion every 24 hours [<xref rid="ofaf012-B4" ref-type="bibr">4</xref>].</p><p>Several studies have suggested that higher doses of daptomycin are safe: &#x02265;8 to 10&#x02005;mg/kg for methicillin-resistant <italic toggle="yes">S aureus</italic> (MRSA) and &#x02265;8 to 12&#x02005;mg/kg for vancomycin-resistant <italic toggle="yes">Enterococcus</italic> spp. May be associated with better clinical outcomes, and they have been shown to be appropriate [<xref rid="ofaf012-B7" ref-type="bibr">7&#x02013;12</xref>]. Fowler et al performed an open-label study that compared daptomycin with the standard therapy for bacteremia and endocarditis staphylococcus infections and concluded that daptomycin at 6&#x02005;mg/kg once daily was noninferior to the standard therapy in bacteremia and right-sided endocarditis caused by MRSA or MSSA [<xref rid="ofaf012-B13" ref-type="bibr">13</xref>]. A single retrospective study also concluded that daptomycin (median dose, 7&#x02005;mg/kg) may be comparable to the ASBLs in the treatment of MSSA BSIs, as there were no differences in the clinical outcomes [<xref rid="ofaf012-B14" ref-type="bibr">14</xref>]. Chastain et al compared the efficacy of antimicrobial therapies used in the management of persistent MSSA BSIs and suggested that daptomycin might be an alternative in patients with persistent bacteremia [<xref rid="ofaf012-B15" ref-type="bibr">15</xref>]. Similarly, a study evaluated the efficacy of high doses of daptomycin (&#x02265;8&#x02005;mg/kg) vs lower doses (4 to 7&#x02005;mg/kg) and found better treatment success with the higher doses [<xref rid="ofaf012-B16" ref-type="bibr">16</xref>].</p><p>However, optimal daptomycin dosing in MSSA BSI is not as well established. To address this important knowledge gap, we conducted a multicenter, retrospective, observational cohort study to evaluate whether composite treatment failure was improved in patients with MSSA BSI who received high-dose daptomycin (&#x02265;8&#x02005;mg/kg) vs those who received standard dosing (&#x0003c;8&#x02005;mg/kg).</p><sec sec-type="methods" id="ofaf012-s1"><title>METHODS</title><p>This institutional review board&#x02013;approved multicenter, retrospective, observational cohort study was conducted in the Intermountain Health integrated health system. We included all adult patients admitted with MSSA BSI to 1 of 22 Intermountain hospitals between 1 January 2010 and 31 October 2023 who had an OPAT discharge with daptomycin. A combination of electronic and manual chart review was then performed with 2 types of electronic health record software: iCentra (Cerner) and Help2. Electronic data such as admission, discharge, dosing, and laboratory values were pulled by 1 of the investigators. A manual chart review was conducted to include data that could not be collected electronically and to confirm diagnosis, discharge, and readmission information. Three independent reviewers followed the data collection protocol with any ambiguity being addressed with the primary investigator. Patients were excluded if they were being actively treated for malignancy, died in the hospital, or were discharged with hospice, due to the potential to skew outcomes (<xref rid="ofaf012-F1" ref-type="fig">Figure 1</xref>). Protected health populations were also excluded. The study population was divided into 2 study groups based on their dose of daptomycin at discharge: standard dose (SD; &#x0003c;8&#x02005;mg/kg) and high dose (HD; &#x02265;8&#x02005;mg/kg) according to adjusted body weight (ABW). ABW was calculated with following equation: ideal body weight + 0.4 &#x000d7; (ABW &#x02212; ideal body weight).</p><fig position="float" id="ofaf012-F1" fig-type="figure"><label>Figure 1.</label><caption><p>Patients identified to fit the inclusion criteria. BSI, bloodstream infection; HD, high dose; MSSA, methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic>; OPAT, outpatient parenteral antibiotic therapy; SD, standard dose.</p></caption><graphic xlink:href="ofaf012f1" position="float"/></fig><p>The primary outcome was composite treatment failure within 90 days of discharge, defined as any of the following: infection-related readmission, MSSA BSI recurrence, change of antimicrobial agents, and/or mortality [<xref rid="ofaf012-B6" ref-type="bibr">6</xref>]. Secondary outcomes included highest observed creatine kinase (CK) elevation, incidence of diagnosed eosinophilic pneumonia, and comparison of ABW vs total body weight in persons with obesity (body mass index &#x02265;30&#x02005;kg/m<sup>2</sup>).</p><sec id="ofaf012-s1.1"><title>Statistical Analysis</title><p>To mitigate indication bias, we developed a propensity model by fitting a logistic regression model with HD vs SD as the dependent variable and with the following adjuster covariates: age, weight, body mass index, sex, race, Charlson Comorbidity Index, Pitt score, follow-up blood cultures with positive results beyond 48&#x02005;hours, serum creatinine, statin use, primary source of infection, and intensive care unit admission during hospitalization. The primary source of infection was determined by the diagnosis of endocarditis, and for those patients without endocarditis, the primary source of infection was used as the diagnosis. Those without any endocarditis or other known infection were labeled as infections of unknown source. Additionally, complicated bacteremia was defined as patients with positive blood culture results and any of the following: endocarditis, implanted prostheses, positive follow-up blood cultures obtained 48 to 96&#x02005;hours after the initial set, continued fevers past 72hours, and evidence of metastatic sites of infection [<xref rid="ofaf012-B7" ref-type="bibr">7</xref>]. Uncomplicated bacteremia was defined as none of the aforementioned. The subcomponents of complicated bacteremia were also integrated into our propensity model. Source control was defined as surgical intervention and/or negative follow-up blood culture results. Because hospital site was strongly collinear with daptomycin dose selection due to variation among hospital-based infectious disease practices, inclusion of hospital in the propensity model led to nonconvergence and obscured the effect of other variables. We therefore conducted a prespecified sensitivity analysis by fitting a separate propensity model including hospital sites as the only adjuster variable to determine if unmeasured confounders due to other differences in practice that vary by site may be influencing the outcome.</p><p>The primary and secondary analyses were then conducted by fitting a logistic regression model with the propensity score to perform inverse probability of treatment weighting (IPTW). Weights were truncated at their 2.5th and 97.5th percentiles to prevent outliers from influencing effect estimates. Standardized mean differences in confounder variables between groups were plotted before and after IPTW. Statistical analysis was performed with R version 4.2.3 (R Project for Statistical Computing).</p></sec></sec><sec sec-type="results" id="ofaf012-s2"><title>RESULTS</title><p>Between January 2010 and October 2023, 150 patients met inclusion criteria, among whom the composite treatment failure at 90 days occurred in 66 (44%). Individual components of the primary outcome were as follows: readmission, 62 patients (41%); mortality, 6 (4%); recurrence of bacteremia, 8 (5%); and antibiotic change, 9 (6%). Adverse events were rare: CK abnormalities occurred in 5 patients (3%), and a diagnosed incidence of eosinophilic pneumonia occurred in 1 patient (1%) who received HD daptomycin. Of the 150 patients, 74 (49%) received SD and 76 (51%) received HD. Overall, 3 patients in the HD group had an SD dosing while hospitalized; all other daptomycin doses were the same at discharge. Groups were similar in terms of age, gender, weight, and complications of infection (<xref rid="ofaf012-T1" ref-type="table">Table 1</xref>). Patients in the HD group had more comorbidities but lower frequency of intensive care unit stays. After IPTW, standardized mean differences were minimized to &#x0003c;0.1 in all variables of interest.</p><table-wrap position="float" id="ofaf012-T1"><label>Table 1.</label><caption><p>Baseline Characteristics and Primary and Secondary Outcomes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">Unadjusted, No. (%) or Median (IQR)</th><th align="center" colspan="4" rowspan="1">Propensity-Weighted Cohort, % or Median (IQR)</th></tr><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">SD (n = 74)</th><th align="center" rowspan="1" colspan="1">HD (n = 76)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th><th align="center" rowspan="1" colspan="1">SMD</th><th align="center" rowspan="1" colspan="1">SD (n = 146.3)</th><th align="center" rowspan="1" colspan="1">HD (n = 146.4)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th><th align="center" rowspan="1" colspan="1">SMD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Site</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;.001</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Telehealth</td><td rowspan="1" colspan="1">11 (14.9)</td><td rowspan="1" colspan="1">14 (18.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.035</td><td rowspan="1" colspan="1">12.3</td><td rowspan="1" colspan="1">20.9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.086</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IMC</td><td rowspan="1" colspan="1">5 (6.8)</td><td rowspan="1" colspan="1">17 (22.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.156</td><td rowspan="1" colspan="1">6.5</td><td rowspan="1" colspan="1">23.1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.166</td></tr><tr><td rowspan="1" colspan="1">&#x02003;McKay-Dee Hospital</td><td rowspan="1" colspan="1">19 (25.7)</td><td rowspan="1" colspan="1">25 (32.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.072</td><td rowspan="1" colspan="1">28.2</td><td rowspan="1" colspan="1">26.3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.019</td></tr><tr><td rowspan="1" colspan="1">&#x02003;St George Regional Hospital</td><td rowspan="1" colspan="1">37 (50.0)</td><td rowspan="1" colspan="1">6 (7.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.421</td><td rowspan="1" colspan="1">51.3</td><td rowspan="1" colspan="1">10.0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.413</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Utah Valley Hospital</td><td rowspan="1" colspan="1">2 (2.7)</td><td rowspan="1" colspan="1">14 (18.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.157</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">19.7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.181</td></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">22 (29.7)</td><td rowspan="1" colspan="1">29 (38.2)</td><td rowspan="1" colspan="1">.359</td><td rowspan="1" colspan="1">0.179</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">34.9</td><td rowspan="1" colspan="1">.835</td><td rowspan="1" colspan="1">0.019</td></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.496</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.957</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;White</td><td rowspan="1" colspan="1">66 (89.2)</td><td rowspan="1" colspan="1">66 (86.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.024</td><td rowspan="1" colspan="1">90.4</td><td rowspan="1" colspan="1">89.4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.01</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unknown</td><td rowspan="1" colspan="1">4 (5.4)</td><td rowspan="1" colspan="1">6 (7.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.025</td><td rowspan="1" colspan="1">5.0</td><td rowspan="1" colspan="1">6.1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">Age, y</td><td rowspan="1" colspan="1">61.5 (43.00&#x02013;70.75)</td><td rowspan="1" colspan="1">58.5 (43.00&#x02013;71.25)</td><td rowspan="1" colspan="1">.826</td><td rowspan="1" colspan="1">0.033</td><td rowspan="1" colspan="1">60.36 (43.0&#x02013;71.56)</td><td rowspan="1" colspan="1">59.0 (45.0&#x02013;71.0)</td><td rowspan="1" colspan="1">.915</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">Pitt score</td><td rowspan="1" colspan="1">1 (0.00&#x02013;1.00)</td><td rowspan="1" colspan="1">1 (1&#x02013;2.25)</td><td rowspan="1" colspan="1">.077</td><td rowspan="1" colspan="1">0.357</td><td rowspan="1" colspan="1">1 (1&#x02013;2)</td><td rowspan="1" colspan="1">1 (0&#x02013;2)</td><td rowspan="1" colspan="1">.918</td><td rowspan="1" colspan="1">0.035</td></tr><tr><td rowspan="1" colspan="1">CCI</td><td rowspan="1" colspan="1">3 (1&#x02013;6)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">.217</td><td rowspan="1" colspan="1">0.178</td><td rowspan="1" colspan="1">4 (1&#x02013;6.91)</td><td rowspan="1" colspan="1">4 (2&#x02013;6)</td><td rowspan="1" colspan="1">.820</td><td rowspan="1" colspan="1">0.032</td></tr><tr><td rowspan="1" colspan="1">Weight, kg</td><td rowspan="1" colspan="1">83.8 (72.00&#x02013;97.43)</td><td rowspan="1" colspan="1">90.75 (75.9&#x02013;106.82)</td><td rowspan="1" colspan="1">.06</td><td rowspan="1" colspan="1">0.285</td><td rowspan="1" colspan="1">86 (72.98&#x02013;98.49)</td><td rowspan="1" colspan="1">90.25 (74.69&#x02013;104.9)</td><td rowspan="1" colspan="1">.453</td><td rowspan="1" colspan="1">0.089</td></tr><tr><td rowspan="1" colspan="1">Adjusted body weight, kg</td><td rowspan="1" colspan="1">75.98 (66.84&#x02013;83.35)</td><td rowspan="1" colspan="1">79.50 (65.69&#x02013;86.51)</td><td rowspan="1" colspan="1">.243</td><td rowspan="1" colspan="1">0.148</td><td rowspan="1" colspan="1">75.97 (67.8&#x02013;84.17)</td><td rowspan="1" colspan="1">80.23 (65.66&#x02013;85.69)</td><td rowspan="1" colspan="1">.482</td><td rowspan="1" colspan="1">0.066</td></tr><tr><td rowspan="1" colspan="1">Serum creatinine</td><td rowspan="1" colspan="1">1.03 (0.78&#x02013;1.48)</td><td rowspan="1" colspan="1">0.93 (0.80&#x02013;1.24)</td><td rowspan="1" colspan="1">.180</td><td rowspan="1" colspan="1">0.391</td><td rowspan="1" colspan="1">0.95 (0.76&#x02013;1.36)</td><td rowspan="1" colspan="1">0.97 (0.83&#x02013;1.39)</td><td rowspan="1" colspan="1">.581</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">Daptomycin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Dose, mg</td><td rowspan="1" colspan="1">500 (405&#x02013;590)</td><td rowspan="1" colspan="1">700 (600&#x02013;800)</td><td rowspan="1" colspan="1">&#x0003c;.001</td><td rowspan="1" colspan="1">1.635</td><td rowspan="1" colspan="1">500 (400&#x02013;600)</td><td rowspan="1" colspan="1">700 (600&#x02013;800)</td><td rowspan="1" colspan="1">&#x0003c;.001</td><td rowspan="1" colspan="1">1.494</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dose, mg/kg, adjusted body weight</td><td rowspan="1" colspan="1">6.54 (6.06&#x02013;7.20)</td><td rowspan="1" colspan="1">9.02 (8.33&#x02013;9.88)</td><td rowspan="1" colspan="1">&#x0003c;.001</td><td rowspan="1" colspan="1">2.913</td><td rowspan="1" colspan="1">6.52 (6.03&#x02013;7.22)</td><td rowspan="1" colspan="1">8.83 (8.26&#x02013;9.73)</td><td rowspan="1" colspan="1">&#x0003c;.001</td><td rowspan="1" colspan="1">2.752</td></tr><tr><td rowspan="1" colspan="1">Positive follow-up blood culture &#x02265;48&#x02005;h</td><td rowspan="1" colspan="1">9 (12.2)</td><td rowspan="1" colspan="1">7 (9.2)</td><td rowspan="1" colspan="1">.748</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">9.7</td><td rowspan="1" colspan="1">9.9</td><td rowspan="1" colspan="1">.959</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Infectious disease consult</td><td rowspan="1" colspan="1">68 (91.9)</td><td rowspan="1" colspan="1">71 (93.4)</td><td rowspan="1" colspan="1">.963</td><td rowspan="1" colspan="1">0.015</td><td rowspan="1" colspan="1">92.1</td><td rowspan="1" colspan="1">93.6</td><td rowspan="1" colspan="1">.733</td><td rowspan="1" colspan="1">0.015</td></tr><tr><td rowspan="1" colspan="1">Documented negative blood culture</td><td rowspan="1" colspan="1">71 (95.9)</td><td rowspan="1" colspan="1">75 (98.7)</td><td rowspan="1" colspan="1">.593</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">97.6</td><td rowspan="1" colspan="1">98.7</td><td rowspan="1" colspan="1">.567</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">Source of infection</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.844</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;.99</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Central nervous system</td><td rowspan="1" colspan="1">8 (10.8)</td><td rowspan="1" colspan="1">8 (10.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.003</td><td rowspan="1" colspan="1">12.7</td><td rowspan="1" colspan="1">12.6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;SSTI/DFI</td><td rowspan="1" colspan="1">21 (28.4)</td><td rowspan="1" colspan="1">18 (23.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.047</td><td rowspan="1" colspan="1">27.7</td><td rowspan="1" colspan="1">25.9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.018</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Gastrointestinal/genitourinary</td><td rowspan="1" colspan="1">5 (6.8)</td><td rowspan="1" colspan="1">4 (5.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.015</td><td rowspan="1" colspan="1">4.6</td><td rowspan="1" colspan="1">4.3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.003</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Infective endocarditis</td><td rowspan="1" colspan="1">3 (4.1)</td><td rowspan="1" colspan="1">6 (7.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.038</td><td rowspan="1" colspan="1">5.0</td><td rowspan="1" colspan="1">5.9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.009</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IOUS/IVDU</td><td rowspan="1" colspan="1">14 (18.9)</td><td rowspan="1" colspan="1">11 (14.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.044</td><td rowspan="1" colspan="1">16.4</td><td rowspan="1" colspan="1">17.0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Osteo/joint</td><td rowspan="1" colspan="1">10 (13.5)</td><td rowspan="1" colspan="1">15 (19.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.062</td><td rowspan="1" colspan="1">15.5</td><td rowspan="1" colspan="1">15.4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Line</td><td rowspan="1" colspan="1">13 (17.6)</td><td rowspan="1" colspan="1">14 (18.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.008</td><td rowspan="1" colspan="1">18.2</td><td rowspan="1" colspan="1">18.9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">Intensive care unit</td><td rowspan="1" colspan="1">10 (13.5)</td><td rowspan="1" colspan="1">6 (7.9)</td><td rowspan="1" colspan="1">.395</td><td rowspan="1" colspan="1">&#x02212;0.056</td><td rowspan="1" colspan="1">13.7</td><td rowspan="1" colspan="1">12.3</td><td rowspan="1" colspan="1">.844</td><td rowspan="1" colspan="1">&#x02212;0.014</td></tr><tr><td rowspan="1" colspan="1">Complicated infection</td><td rowspan="1" colspan="1">56 (75.7)</td><td rowspan="1" colspan="1">57 (75)</td><td rowspan="1" colspan="1">&#x0003e;.99</td><td rowspan="1" colspan="1">&#x02212;0.007</td><td rowspan="1" colspan="1">73.1</td><td rowspan="1" colspan="1">76.7</td><td rowspan="1" colspan="1">.655</td><td rowspan="1" colspan="1">0.036</td></tr><tr><td rowspan="1" colspan="1">No. of source control interventions</td><td rowspan="1" colspan="1">0 (0&#x02013;1)</td><td rowspan="1" colspan="1">1 (0&#x02013;1)</td><td rowspan="1" colspan="1">.088</td><td rowspan="1" colspan="1">0.276</td><td rowspan="1" colspan="1">0 (0&#x02013;1)</td><td rowspan="1" colspan="1">1 (0&#x02013;1)</td><td rowspan="1" colspan="1">.357</td><td rowspan="1" colspan="1">0.157</td></tr><tr><td rowspan="1" colspan="1">Statin</td><td rowspan="1" colspan="1">18 (24.3)</td><td rowspan="1" colspan="1">22 (28.9)</td><td rowspan="1" colspan="1">.649</td><td rowspan="1" colspan="1">0.046</td><td rowspan="1" colspan="1">25.6</td><td rowspan="1" colspan="1">25.1</td><td rowspan="1" colspan="1">.951</td><td rowspan="1" colspan="1">&#x02212;0.005</td></tr><tr><td rowspan="1" colspan="1">Length of stay, d</td><td rowspan="1" colspan="1">6 (4&#x02013;9)</td><td rowspan="1" colspan="1">6 (4.75&#x02013;8)</td><td rowspan="1" colspan="1">.654</td><td rowspan="1" colspan="1">0.093</td><td rowspan="1" colspan="1">6 (4&#x02013;9)</td><td rowspan="1" colspan="1">6 (4&#x02013;8.27)</td><td rowspan="1" colspan="1">.762</td><td rowspan="1" colspan="1">0.091</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: CCI, Charlson comorbidity index; DFI, diabetic foot infection; HD, high dose; IMC, Intermountain Medical Center; IOUS, unknown source of infection; IVDU, intravenous drug use; SD, standard dose; SMD, standardized mean difference; SSTI, skin soft tissue infection.</p></fn></table-wrap-foot></table-wrap><p>Unadjusted composite treatment failure at 90 days occurred in 27 (36%) and 39 (53%) patients in the HD and SD groups, respectively. In the primary analysis (<xref rid="ofaf012-T2" ref-type="table">Table 2</xref>), composite treatment failure at 90 days was lower in the HD group relative to the SD group (odds ratio [OR], 0.496; 95% CI, .306&#x02013;.804). The individual components of the composite outcome within 90 days were as follows: readmission (OR, 0.516; 95% CI, .317&#x02013;.839), mortality (OR, 0.356; 95% CI, .0713&#x02013;1.780), recurrence of bacteremia (OR, 0.382; 95% CI, .130&#x02013;1.124), and antibiotic change (OR, 0.456; 95% CI, .166&#x02013;1.252). Results were robust to the prespecified sensitivity analysis (OR, 0.61; 95% CI, .39&#x02013;.97).</p><table-wrap position="float" id="ofaf012-T2"><label>Table 2.</label><caption><p>IPTW Adjusted Primary and Secondary Outcomes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Odds Ratio (95% CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Primary end point</td><td rowspan="1" colspan="1">0.496 (.306&#x02013;.804)</td></tr><tr><td rowspan="1" colspan="1">90 d</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Readmission</td><td rowspan="1" colspan="1">0.516 (.317&#x02013;.839)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Death</td><td rowspan="1" colspan="1">0.356 (.0713&#x02013;1.780)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Recurrence</td><td rowspan="1" colspan="1">0.382 (.130&#x02013;1.124)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Antimicrobial change</td><td rowspan="1" colspan="1">0.456 (.166&#x02013;1.252)</td></tr><tr><td rowspan="1" colspan="1">CK &#x0003e;1000 U/L</td><td rowspan="1" colspan="1">0.920 (.227&#x02013;3.724)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>Abbreviations: CK, creatine kinase; IPTW, inverse probability of treatment weighting.</p></fn></table-wrap-foot></table-wrap><p>There was no difference between the HD and SD groups in regard to safety outcomes, including CK &#x02265;1000 U/L (3.9% vs 2.7%, respectively; OR, 0.96; 95% CI, .24&#x02013;3.86) and a single diagnosed incidence of eosinophilic pneumonia (1.3%) in the HD group and no cases in the SD group.</p></sec><sec sec-type="discussion" id="ofaf012-s3"><title>DISCUSSION</title><p>Daptomycin offers an advantage as a once-daily 2- to 5-minute infusion in patients with MSSA BSI OPAT as compared with ASBLs [<xref rid="ofaf012-B4" ref-type="bibr">4</xref>]. Several studies have suggested HD daptomycin as compared with SD due to higher treatment success [<xref rid="ofaf012-B13" ref-type="bibr">13</xref>, <xref rid="ofaf012-B15" ref-type="bibr">15&#x02013;17</xref>]. The results from this study indicate that there was a decrease in treatment failure with HD daptomycin when compared with SD. Overall, given the mechanism of action of daptomycin, the <italic toggle="yes">mecA</italic> gene is irrelevant, and similar high daptomycin dosing strategies for MRSA infections should be applicable to MSSA infections.</p><p>Readmission was a major driver in the primary composite outcome with lower readmission in the HD group. Although the primary source of infection was not significant, it appears that higher doses of daptomycin were used in severe infections (joint, infective endocarditis, and unknown source of infection). In terms of safety, there was no difference between the groups; however, we had a small sample size.</p><p>This study is not without limitations, given the retrospective nature and cohort study design, as well as the fact that not all confounding factors could be fully mitigated. There was potential incomplete data due to transfer between 2 electronic health records. Our assumption of source control was either surgical intervention and negative follow-up blood culture results or those who did not have surgical intervention and negative follow-up blood culture results. Overall, the SD group had documented clearance of BSI in 95.9% of patients as compared with the HD group with 98.4% (<italic toggle="yes">P</italic> = .6). Additionally, the primary treatment received before discharge with daptomycin OPAT could have affected the primary outcome as well. This study had a small sample size and a less diverse patient population. We did not evaluate cost-effectiveness, which is another important consideration.</p><p>Future studies are warranted to evaluate CK, incidences of diagnosed eosinophilic pneumonia in a larger population, and optimal dosing management in persons with obesity (body mass index &#x0003e;40&#x02005;kg/m<sup>2</sup>).</p></sec><sec id="ofaf012-s4"><title>CONCLUSION</title><p>There was a statistically significant difference in the composite outcome: 90-day treatment failure between the HD and SD groups. The HD daptomycin group demonstrated lower treatment failure, with less readmission being the major driving factor. The secondary safety outcomes were similar between the groups. Overall, the results from this study suggest that HD daptomycin may be preferred in patients discharged with OPAT for MSSA BSIs.</p></sec></body><back><sec id="ofaf012-s5"><title>Notes</title><p>
<bold>
<italic toggle="yes">Acknowledgments.</italic>
</bold> We acknowledge Amy S. Childress, MA, for technical formatting of the manuscript.</p><p>
<italic toggle="yes">
<bold>Financial support.</bold>
</italic> All authors state that this work was not directly supported by any funding agencies.</p><p>
<bold>
<italic toggle="yes">Patient consent statement.</italic>
</bold> The design of the work has been approved by Intermountain Health institutional review board ethical committees, or it conforms to standards currently applied in the country of origin and includes the name of the authorizing body stated in the brief report.</p></sec><ref-list id="ref1"><title>References</title><ref id="ofaf012-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wiggli</surname> &#x000a0;<given-names>BJ</given-names></string-name>, <string-name><surname>Frei</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Laffer</surname> &#x000a0;<given-names>R</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Survival from methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> bloodstream infections over 20 years: a cohort of 1328 patients</article-title>. <source>Swiss Med Wkly</source> &#x000a0;<year>2017</year>; <volume>147</volume>:<fpage>w14508</fpage>.<pub-id pub-id-type="pmid">28975960</pub-id>
</mixed-citation></ref><ref id="ofaf012-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hassoun</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Linden</surname> &#x000a0;<given-names>PK</given-names></string-name>, <string-name><surname>Friedman</surname> &#x000a0;<given-names>B</given-names></string-name></person-group>. <article-title>Incidence, prevalence, and management of MRSA bacteremia across patient populations&#x02014;a review of recent developments in MRSA management and treatment</article-title>. <source>Crit Care</source> &#x000a0;<year>2017</year>; <volume>21</volume>:<fpage>211</fpage>.<pub-id pub-id-type="pmid">28807042</pub-id>
</mixed-citation></ref><ref id="ofaf012-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hindy</surname> &#x000a0;<given-names>JR</given-names></string-name>, <string-name><surname>Quintero-Martinez</surname> &#x000a0;<given-names>JA</given-names></string-name>, <string-name><surname>Lahr</surname> &#x000a0;<given-names>BD</given-names></string-name>, <string-name><surname>DeSimone</surname> &#x000a0;<given-names>DC</given-names></string-name>, <string-name><surname>Baddour</surname> &#x000a0;<given-names>LM</given-names></string-name></person-group>. <article-title><italic toggle="yes">Staphylococcus aureus</italic> bacteraemia and mortality: a population-based study in Olmsted County, Minnesota, from 2006 to 2020</article-title>. <source>Infect Dis (Lond)</source> &#x000a0;<year>2023</year>; <volume>55</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">36151989</pub-id>
</mixed-citation></ref><ref id="ofaf012-B4"><label>4</label><mixed-citation publication-type="other">
<comment>Merck &#x00026; Co. Daptomycin injection solution. Package insert. Whitehouse Station, NJ: Merck &#x00026; Co; 2023.</comment>
</mixed-citation></ref><ref id="ofaf012-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nannini</surname> &#x000a0;<given-names>EC</given-names></string-name>, <string-name><surname>Singh</surname> &#x000a0;<given-names>KV</given-names></string-name>, <string-name><surname>Arias</surname> &#x000a0;<given-names>CA</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>In vivo effects of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> strain showing an inoculum effect against cefazolin</article-title>. <source>Antimicrob Agents Chemother</source> &#x000a0;<year>2013</year>; <volume>57</volume>:<fpage>4276</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">23796934</pub-id>
</mixed-citation></ref><ref id="ofaf012-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tong</surname> &#x000a0;<given-names>SYC</given-names></string-name>, <string-name><surname>Lye</surname> &#x000a0;<given-names>DC</given-names></string-name>, <string-name><surname>Yahav</surname> &#x000a0;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Effect of vancomycin or daptomycin with vs without an antistaphylococcal &#x003b2;-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial</article-title>. <source>JAMA</source> &#x000a0;<year>2020</year>; <volume>323</volume>:<fpage>527</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">32044943</pub-id>
</mixed-citation></ref><ref id="ofaf012-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Bayer</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Cosgrove</surname> &#x000a0;<given-names>SE</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> infections in adults and children: executive summary</article-title>. <source>Clin Infect Dis</source> &#x000a0;<year>2011</year>; <volume>52</volume>:<fpage>285</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">21217178</pub-id>
</mixed-citation></ref><ref id="ofaf012-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Holubar</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Meng</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Alegria</surname> &#x000a0;<given-names>W</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Bacteremia due to methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>: an update on new therapeutic approaches</article-title>. <source>Infect Dis Clin North Am</source> &#x000a0;<year>2020</year>; <volume>34</volume>:<fpage>849</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">33011050</pub-id>
</mixed-citation></ref><ref id="ofaf012-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Foolad</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Taylor</surname> &#x000a0;<given-names>BD</given-names></string-name>, <string-name><surname>Shelburne</surname> &#x000a0;<given-names>SA</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review</article-title>. <source>J Antimicrob Chemother</source> &#x000a0;<year>2018</year>; <volume>73</volume>:<fpage>2277</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">29547977</pub-id>
</mixed-citation></ref><ref id="ofaf012-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Timbrook</surname> &#x000a0;<given-names>TT</given-names></string-name>, <string-name><surname>Caffrey</surname> &#x000a0;<given-names>AR</given-names></string-name>, <string-name><surname>Luther</surname> &#x000a0;<given-names>MK</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Association of higher daptomycin dose (7&#x02005;mg/kg or greater) with improved survival in patients with methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> bacteremia</article-title>. <source>Pharmacotherapy</source> &#x000a0;<year>2018</year>; <volume>38</volume>:<fpage>189</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">29235661</pub-id>
</mixed-citation></ref><ref id="ofaf012-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zasowski</surname> &#x000a0;<given-names>EJ</given-names></string-name>, <string-name><surname>Trinh</surname> &#x000a0;<given-names>TD</given-names></string-name>, <string-name><surname>Claeys</surname> &#x000a0;<given-names>KC</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> bloodstream infection</article-title>. <source>Open Forum Infect Dis</source> &#x000a0;<year>2021</year>; <volume>9</volume>:<fpage>ofab606</fpage>.<pub-id pub-id-type="pmid">35146040</pub-id>
</mixed-citation></ref><ref id="ofaf012-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Benvenuto</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Benziger</surname> &#x000a0;<given-names>DP</given-names></string-name>, <string-name><surname>Yankelev</surname> &#x000a0;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers</article-title>. <source>Antimicrob Agents Chemother</source> &#x000a0;<year>2006</year>; <volume>50</volume>:<fpage>3245</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17005801</pub-id>
</mixed-citation></ref><ref id="ofaf012-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fowler</surname> &#x000a0;<given-names>VG</given-names> &#x000a0;<suffix>Jr</suffix></string-name>, <string-name><surname>Boucher</surname> &#x000a0;<given-names>HW</given-names></string-name>, <string-name><surname>Corey</surname> &#x000a0;<given-names>GR</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Daptomycin versus standard therapy for bacteremia and endocarditis caused by <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>N Engl J Med</source> &#x000a0;<year>2006</year>; <volume>355</volume>:<fpage>653</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">16914701</pub-id>
</mixed-citation></ref><ref id="ofaf012-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Agnello</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Wardlow</surname> &#x000a0;<given-names>LC</given-names></string-name>, <string-name><surname>Reed</surname> &#x000a0;<given-names>E</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Clinical outcomes of daptomycin versus anti-staphylococcal beta-lactams in definitive treatment of methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> bloodstream infections</article-title>. <source>Int J Antimicrob Agents</source> &#x000a0;<year>2021</year>; <volume>58</volume>:<fpage>106363</fpage>.<pub-id pub-id-type="pmid">34033912</pub-id>
</mixed-citation></ref><ref id="ofaf012-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chastain</surname> &#x000a0;<given-names>DB</given-names></string-name>, <string-name><surname>Covert</surname> &#x000a0;<given-names>KL</given-names></string-name>, <string-name><surname>Tu</surname> &#x000a0;<given-names>PJ</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Therapeutic options for adult patients with persistent methicillin-susceptible <italic toggle="yes">Staphylococcus aureus</italic> bacteremia: a narrative review</article-title>. <source>Ann Pharmacother</source> &#x000a0;<year>2023</year>; <volume>57</volume>:<fpage>1312&#x02013;</fpage><lpage>27</lpage>.<pub-id pub-id-type="pmid">36946576</pub-id>
</mixed-citation></ref><ref id="ofaf012-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Samura</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Takada</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Hirose</surname> &#x000a0;<given-names>N</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Comparison of the efficacy and safety of standard- and high-dose daptomycin: a systematic review and meta-analysis</article-title>. <source>Br J Clin Pharmacol</source> &#x000a0;<year>2023</year>; <volume>89</volume>:<fpage>1291</fpage>&#x02013;<lpage>303</lpage>.<pub-id pub-id-type="pmid">36693240</pub-id>
</mixed-citation></ref><ref id="ofaf012-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seaton</surname> &#x000a0;<given-names>RA</given-names></string-name>, <string-name><surname>Menichetti</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Dalekos</surname> &#x000a0;<given-names>G</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin outcomes registry and experience</article-title>. <source>Adv Ther</source> &#x000a0;<year>2015</year>; <volume>32</volume>:<fpage>1192</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">26610384</pub-id>
</mixed-citation></ref></ref-list></back></article>